Global Oral Vaccines research

Oral Vaccines Comprehensive Study by Type (Live (attenuated), Inactive, Recombinant, Other), Application (Polio, Rabies, Tuberculosis, Influenza, Respiratory infections, HIV, Cholera, Rotavirus, Others), End Users (Hospitals, Government Vaccination Programs, Clinics, Research Institutes) Players and Region - Global Market Outlook to 2028

Oral Vaccines Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Market Overview:
Vaccination is termed as an economical and efficient means of preventing numerous infectious disorders. The employment of common vaccines has curbed the widespread transmission of diseases like polio and measles in developing as well as developed regions. Oral vaccines exhibit the potential to take immunization to a new level of superiority. Though most vaccines are delivered via the parenteral route, oral vaccines are considered to be a feasible alternative employed for the prevention of non-mucosal transmitted infections. Orally administered vaccines are processed by the digestive tract's immune system, referred to as the gut-associated lymphoid tissue. To increase immunity against important disorders like influenza and TB, new oral vaccines are being produced in developed countries.



AttributesDetails
Study Period2018-2028
Base Year2022
Forecast Period2023-2028
Historical Period2018-2022
UnitValue (USD Million)
Key Companies ProfiledGlaxoSmithKline Plc. (United Kingdom), Merck & Co. Inc. (United States), Aventis (Sanofi S.A.) (France), Swiss Serum and Vaccine Institute Berne (Switzerland), QUÍMICA SUIZA S.A. (Peru), PaxVax Corporation (United States), VALNEVA Canada Inc. (Canada), Janssen Pharmaceuticals (Belgium), Serum Institute of India Pvt. Ltd. (India) and Shanghai BravoBio Co., Ltd. (China)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region or narrow down segments in the final scope subject to feasibility


AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics of major and emerging geographies across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Key Players of Oral Vaccines Market Study:
GlaxoSmithKline Plc. (United Kingdom), Merck & Co. Inc. (United States), Aventis (Sanofi S.A.) (France), Swiss Serum and Vaccine Institute Berne (Switzerland), QUÍMICA SUIZA S.A. (Peru), PaxVax Corporation (United States), VALNEVA Canada Inc. (Canada), Janssen Pharmaceuticals (Belgium), Serum Institute of India Pvt. Ltd. (India) and Shanghai BravoBio Co., Ltd. (China)

Oral Vaccines Market Segment Analysis
ScopeSub-Segments
Application / End UserPolio, Rabies, Tuberculosis, Influenza, Respiratory infections, HIV, Cholera, Rotavirus and Others
TypeLive (attenuated), Inactive, Recombinant and Other
End UsersHospitals,Government Vaccination Programs,Clinics,Research Institutes


Influencing Trend:
New Developments in Oral Vaccines

Market Growth Drivers:
High Prevalence of Infectious Diseases, Rising Focus on Immunization Programs, Growing Government Support for Vaccine Development, Elimination of Needles in the Vaccination Process and Increasing Company Initiatives to Enhance Vaccine R&D

Challenges:
Inadequate Access to Vaccines and Product Recalls

Restraints:
The High Cost of Vaccine Development

Opportunities:
High Growth Prospects in Emerging Markets, Focus On Therapeutic Vaccines and Use of Adjuvants in Vaccines

Some of the other players that are also part of study are TD Vaccines A/S (Denmark), Crucell Vaccines, Inc. (United States), Sublimity Therapeutics Limited (Ireland) and International Vaccine Institute (South Korea). The Global Oral Vaccines market is gaining huge competition due to involvement of United States companies that constantly invest in research & development to meet market expectation with new innovation.

Latest Industry Highlights:
In December 2022, Pfizer Inc and Clear Creek Bio Inc partnered and focused on the discovery and development of a novel class of oral treatment for COVID-19. The collaboration aims to identify a potential drug candidate as Pfizer looks to broaden its anti-infective portfolio.
In October 2022, Today, Pfizer Inc. acquired Biohaven Pharmaceutical Holding Company Ltd. This acquisition includes the renowned migraine therapy, NURTEC® ODT (rimegepant), which offers a groundbreaking approach for the acute treatment and prevention of episodic migraine in adults.


Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Oral Vaccines market.
In order to reach an exhaustive list of functional and relevant players, various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep into important geographies by players, and a thorough validation test is conducted to reach the most relevant players for survey in Oral Vaccines market.
Identification of total players or companies operating in the global market which is further concentrated to fewer or most impacting players which are considered under the report’s scope. In order to make a priority list sorting is done based on revenue generated based on the latest reporting with the help of paid databases such as Factiva, Bloomberg, etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Manufacturers and suppliers of Oral vaccines, Research and development companies, Medical research laboratories, Academic medical centers and universities, Research and consulting firms and Venture capital firms.

This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth, etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that include Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Live (attenuated)
  • Inactive
  • Recombinant
  • Other
By Application
  • Polio
  • Rabies
  • Tuberculosis
  • Influenza
  • Respiratory infections
  • HIV
  • Cholera
  • Rotavirus
  • Others
By End Users
  • Hospitals
  • Government Vaccination Programs
  • Clinics
  • Research Institutes

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. High Prevalence of Infectious Diseases
      • 3.2.2. Rising Focus on Immunization Programs
      • 3.2.3. Growing Government Support for Vaccine Development
      • 3.2.4. Elimination of Needles in the Vaccination Process
      • 3.2.5. Increasing Company Initiatives to Enhance Vaccine R&D
    • 3.3. Market Challenges
      • 3.3.1. Inadequate Access to Vaccines
      • 3.3.2. Product Recalls
    • 3.4. Market Trends
      • 3.4.1. New Developments in Oral Vaccines
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Oral Vaccines, by Type, Application, End Users and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Oral Vaccines (Value)
      • 5.2.1. Global Oral Vaccines by: Type (Value)
        • 5.2.1.1. Live (attenuated)
        • 5.2.1.2. Inactive
        • 5.2.1.3. Recombinant
        • 5.2.1.4. Other
      • 5.2.2. Global Oral Vaccines by: Application (Value)
        • 5.2.2.1. Polio
        • 5.2.2.2. Rabies
        • 5.2.2.3. Tuberculosis
        • 5.2.2.4. Influenza
        • 5.2.2.5. Respiratory infections
        • 5.2.2.6. HIV
        • 5.2.2.7. Cholera
        • 5.2.2.8. Rotavirus
        • 5.2.2.9. Others
      • 5.2.3. Global Oral Vaccines by: End Users (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Government Vaccination Programs
        • 5.2.3.3. Clinics
        • 5.2.3.4. Research Institutes
      • 5.2.4. Global Oral Vaccines Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Oral Vaccines: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline Plc. (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merck & Co. Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Aventis (Sanofi S.A.) (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Swiss Serum and Vaccine Institute Berne (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. QUÍMICA SUIZA S.A. (Peru)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. PaxVax Corporation (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. VALNEVA Canada Inc. (Canada)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Janssen Pharmaceuticals (Belgium)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Serum Institute of India Pvt. Ltd. (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Shanghai BravoBio Co., Ltd. (China)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Oral Vaccines Sale, by Type, Application, End Users and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Oral Vaccines (Value)
      • 7.2.1. Global Oral Vaccines by: Type (Value)
        • 7.2.1.1. Live (attenuated)
        • 7.2.1.2. Inactive
        • 7.2.1.3. Recombinant
        • 7.2.1.4. Other
      • 7.2.2. Global Oral Vaccines by: Application (Value)
        • 7.2.2.1. Polio
        • 7.2.2.2. Rabies
        • 7.2.2.3. Tuberculosis
        • 7.2.2.4. Influenza
        • 7.2.2.5. Respiratory infections
        • 7.2.2.6. HIV
        • 7.2.2.7. Cholera
        • 7.2.2.8. Rotavirus
        • 7.2.2.9. Others
      • 7.2.3. Global Oral Vaccines by: End Users (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Government Vaccination Programs
        • 7.2.3.3. Clinics
        • 7.2.3.4. Research Institutes
      • 7.2.4. Global Oral Vaccines Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Oral Vaccines: by Type(USD Million)
  • Table 2. Oral Vaccines Live (attenuated) , by Region USD Million (2017-2022)
  • Table 3. Oral Vaccines Inactive , by Region USD Million (2017-2022)
  • Table 4. Oral Vaccines Recombinant , by Region USD Million (2017-2022)
  • Table 5. Oral Vaccines Other , by Region USD Million (2017-2022)
  • Table 6. Oral Vaccines: by Application(USD Million)
  • Table 7. Oral Vaccines Polio , by Region USD Million (2017-2022)
  • Table 8. Oral Vaccines Rabies , by Region USD Million (2017-2022)
  • Table 9. Oral Vaccines Tuberculosis , by Region USD Million (2017-2022)
  • Table 10. Oral Vaccines Influenza , by Region USD Million (2017-2022)
  • Table 11. Oral Vaccines Respiratory infections , by Region USD Million (2017-2022)
  • Table 12. Oral Vaccines HIV , by Region USD Million (2017-2022)
  • Table 13. Oral Vaccines Cholera , by Region USD Million (2017-2022)
  • Table 14. Oral Vaccines Rotavirus , by Region USD Million (2017-2022)
  • Table 15. Oral Vaccines Others , by Region USD Million (2017-2022)
  • Table 16. Oral Vaccines: by End Users(USD Million)
  • Table 17. Oral Vaccines Hospitals , by Region USD Million (2017-2022)
  • Table 18. Oral Vaccines Government Vaccination Programs , by Region USD Million (2017-2022)
  • Table 19. Oral Vaccines Clinics , by Region USD Million (2017-2022)
  • Table 20. Oral Vaccines Research Institutes , by Region USD Million (2017-2022)
  • Table 21. South America Oral Vaccines, by Country USD Million (2017-2022)
  • Table 22. South America Oral Vaccines, by Type USD Million (2017-2022)
  • Table 23. South America Oral Vaccines, by Application USD Million (2017-2022)
  • Table 24. South America Oral Vaccines, by End Users USD Million (2017-2022)
  • Table 25. Brazil Oral Vaccines, by Type USD Million (2017-2022)
  • Table 26. Brazil Oral Vaccines, by Application USD Million (2017-2022)
  • Table 27. Brazil Oral Vaccines, by End Users USD Million (2017-2022)
  • Table 28. Argentina Oral Vaccines, by Type USD Million (2017-2022)
  • Table 29. Argentina Oral Vaccines, by Application USD Million (2017-2022)
  • Table 30. Argentina Oral Vaccines, by End Users USD Million (2017-2022)
  • Table 31. Rest of South America Oral Vaccines, by Type USD Million (2017-2022)
  • Table 32. Rest of South America Oral Vaccines, by Application USD Million (2017-2022)
  • Table 33. Rest of South America Oral Vaccines, by End Users USD Million (2017-2022)
  • Table 34. Asia Pacific Oral Vaccines, by Country USD Million (2017-2022)
  • Table 35. Asia Pacific Oral Vaccines, by Type USD Million (2017-2022)
  • Table 36. Asia Pacific Oral Vaccines, by Application USD Million (2017-2022)
  • Table 37. Asia Pacific Oral Vaccines, by End Users USD Million (2017-2022)
  • Table 38. China Oral Vaccines, by Type USD Million (2017-2022)
  • Table 39. China Oral Vaccines, by Application USD Million (2017-2022)
  • Table 40. China Oral Vaccines, by End Users USD Million (2017-2022)
  • Table 41. Japan Oral Vaccines, by Type USD Million (2017-2022)
  • Table 42. Japan Oral Vaccines, by Application USD Million (2017-2022)
  • Table 43. Japan Oral Vaccines, by End Users USD Million (2017-2022)
  • Table 44. India Oral Vaccines, by Type USD Million (2017-2022)
  • Table 45. India Oral Vaccines, by Application USD Million (2017-2022)
  • Table 46. India Oral Vaccines, by End Users USD Million (2017-2022)
  • Table 47. South Korea Oral Vaccines, by Type USD Million (2017-2022)
  • Table 48. South Korea Oral Vaccines, by Application USD Million (2017-2022)
  • Table 49. South Korea Oral Vaccines, by End Users USD Million (2017-2022)
  • Table 50. Taiwan Oral Vaccines, by Type USD Million (2017-2022)
  • Table 51. Taiwan Oral Vaccines, by Application USD Million (2017-2022)
  • Table 52. Taiwan Oral Vaccines, by End Users USD Million (2017-2022)
  • Table 53. Australia Oral Vaccines, by Type USD Million (2017-2022)
  • Table 54. Australia Oral Vaccines, by Application USD Million (2017-2022)
  • Table 55. Australia Oral Vaccines, by End Users USD Million (2017-2022)
  • Table 56. Rest of Asia-Pacific Oral Vaccines, by Type USD Million (2017-2022)
  • Table 57. Rest of Asia-Pacific Oral Vaccines, by Application USD Million (2017-2022)
  • Table 58. Rest of Asia-Pacific Oral Vaccines, by End Users USD Million (2017-2022)
  • Table 59. Europe Oral Vaccines, by Country USD Million (2017-2022)
  • Table 60. Europe Oral Vaccines, by Type USD Million (2017-2022)
  • Table 61. Europe Oral Vaccines, by Application USD Million (2017-2022)
  • Table 62. Europe Oral Vaccines, by End Users USD Million (2017-2022)
  • Table 63. Germany Oral Vaccines, by Type USD Million (2017-2022)
  • Table 64. Germany Oral Vaccines, by Application USD Million (2017-2022)
  • Table 65. Germany Oral Vaccines, by End Users USD Million (2017-2022)
  • Table 66. France Oral Vaccines, by Type USD Million (2017-2022)
  • Table 67. France Oral Vaccines, by Application USD Million (2017-2022)
  • Table 68. France Oral Vaccines, by End Users USD Million (2017-2022)
  • Table 69. Italy Oral Vaccines, by Type USD Million (2017-2022)
  • Table 70. Italy Oral Vaccines, by Application USD Million (2017-2022)
  • Table 71. Italy Oral Vaccines, by End Users USD Million (2017-2022)
  • Table 72. United Kingdom Oral Vaccines, by Type USD Million (2017-2022)
  • Table 73. United Kingdom Oral Vaccines, by Application USD Million (2017-2022)
  • Table 74. United Kingdom Oral Vaccines, by End Users USD Million (2017-2022)
  • Table 75. Netherlands Oral Vaccines, by Type USD Million (2017-2022)
  • Table 76. Netherlands Oral Vaccines, by Application USD Million (2017-2022)
  • Table 77. Netherlands Oral Vaccines, by End Users USD Million (2017-2022)
  • Table 78. Rest of Europe Oral Vaccines, by Type USD Million (2017-2022)
  • Table 79. Rest of Europe Oral Vaccines, by Application USD Million (2017-2022)
  • Table 80. Rest of Europe Oral Vaccines, by End Users USD Million (2017-2022)
  • Table 81. MEA Oral Vaccines, by Country USD Million (2017-2022)
  • Table 82. MEA Oral Vaccines, by Type USD Million (2017-2022)
  • Table 83. MEA Oral Vaccines, by Application USD Million (2017-2022)
  • Table 84. MEA Oral Vaccines, by End Users USD Million (2017-2022)
  • Table 85. Middle East Oral Vaccines, by Type USD Million (2017-2022)
  • Table 86. Middle East Oral Vaccines, by Application USD Million (2017-2022)
  • Table 87. Middle East Oral Vaccines, by End Users USD Million (2017-2022)
  • Table 88. Africa Oral Vaccines, by Type USD Million (2017-2022)
  • Table 89. Africa Oral Vaccines, by Application USD Million (2017-2022)
  • Table 90. Africa Oral Vaccines, by End Users USD Million (2017-2022)
  • Table 91. North America Oral Vaccines, by Country USD Million (2017-2022)
  • Table 92. North America Oral Vaccines, by Type USD Million (2017-2022)
  • Table 93. North America Oral Vaccines, by Application USD Million (2017-2022)
  • Table 94. North America Oral Vaccines, by End Users USD Million (2017-2022)
  • Table 95. United States Oral Vaccines, by Type USD Million (2017-2022)
  • Table 96. United States Oral Vaccines, by Application USD Million (2017-2022)
  • Table 97. United States Oral Vaccines, by End Users USD Million (2017-2022)
  • Table 98. Canada Oral Vaccines, by Type USD Million (2017-2022)
  • Table 99. Canada Oral Vaccines, by Application USD Million (2017-2022)
  • Table 100. Canada Oral Vaccines, by End Users USD Million (2017-2022)
  • Table 101. Mexico Oral Vaccines, by Type USD Million (2017-2022)
  • Table 102. Mexico Oral Vaccines, by Application USD Million (2017-2022)
  • Table 103. Mexico Oral Vaccines, by End Users USD Million (2017-2022)
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. Company Basic Information, Sales Area and Its Competitors
  • Table 114. Oral Vaccines: by Type(USD Million)
  • Table 115. Oral Vaccines Live (attenuated) , by Region USD Million (2023-2028)
  • Table 116. Oral Vaccines Inactive , by Region USD Million (2023-2028)
  • Table 117. Oral Vaccines Recombinant , by Region USD Million (2023-2028)
  • Table 118. Oral Vaccines Other , by Region USD Million (2023-2028)
  • Table 119. Oral Vaccines: by Application(USD Million)
  • Table 120. Oral Vaccines Polio , by Region USD Million (2023-2028)
  • Table 121. Oral Vaccines Rabies , by Region USD Million (2023-2028)
  • Table 122. Oral Vaccines Tuberculosis , by Region USD Million (2023-2028)
  • Table 123. Oral Vaccines Influenza , by Region USD Million (2023-2028)
  • Table 124. Oral Vaccines Respiratory infections , by Region USD Million (2023-2028)
  • Table 125. Oral Vaccines HIV , by Region USD Million (2023-2028)
  • Table 126. Oral Vaccines Cholera , by Region USD Million (2023-2028)
  • Table 127. Oral Vaccines Rotavirus , by Region USD Million (2023-2028)
  • Table 128. Oral Vaccines Others , by Region USD Million (2023-2028)
  • Table 129. Oral Vaccines: by End Users(USD Million)
  • Table 130. Oral Vaccines Hospitals , by Region USD Million (2023-2028)
  • Table 131. Oral Vaccines Government Vaccination Programs , by Region USD Million (2023-2028)
  • Table 132. Oral Vaccines Clinics , by Region USD Million (2023-2028)
  • Table 133. Oral Vaccines Research Institutes , by Region USD Million (2023-2028)
  • Table 134. South America Oral Vaccines, by Country USD Million (2023-2028)
  • Table 135. South America Oral Vaccines, by Type USD Million (2023-2028)
  • Table 136. South America Oral Vaccines, by Application USD Million (2023-2028)
  • Table 137. South America Oral Vaccines, by End Users USD Million (2023-2028)
  • Table 138. Brazil Oral Vaccines, by Type USD Million (2023-2028)
  • Table 139. Brazil Oral Vaccines, by Application USD Million (2023-2028)
  • Table 140. Brazil Oral Vaccines, by End Users USD Million (2023-2028)
  • Table 141. Argentina Oral Vaccines, by Type USD Million (2023-2028)
  • Table 142. Argentina Oral Vaccines, by Application USD Million (2023-2028)
  • Table 143. Argentina Oral Vaccines, by End Users USD Million (2023-2028)
  • Table 144. Rest of South America Oral Vaccines, by Type USD Million (2023-2028)
  • Table 145. Rest of South America Oral Vaccines, by Application USD Million (2023-2028)
  • Table 146. Rest of South America Oral Vaccines, by End Users USD Million (2023-2028)
  • Table 147. Asia Pacific Oral Vaccines, by Country USD Million (2023-2028)
  • Table 148. Asia Pacific Oral Vaccines, by Type USD Million (2023-2028)
  • Table 149. Asia Pacific Oral Vaccines, by Application USD Million (2023-2028)
  • Table 150. Asia Pacific Oral Vaccines, by End Users USD Million (2023-2028)
  • Table 151. China Oral Vaccines, by Type USD Million (2023-2028)
  • Table 152. China Oral Vaccines, by Application USD Million (2023-2028)
  • Table 153. China Oral Vaccines, by End Users USD Million (2023-2028)
  • Table 154. Japan Oral Vaccines, by Type USD Million (2023-2028)
  • Table 155. Japan Oral Vaccines, by Application USD Million (2023-2028)
  • Table 156. Japan Oral Vaccines, by End Users USD Million (2023-2028)
  • Table 157. India Oral Vaccines, by Type USD Million (2023-2028)
  • Table 158. India Oral Vaccines, by Application USD Million (2023-2028)
  • Table 159. India Oral Vaccines, by End Users USD Million (2023-2028)
  • Table 160. South Korea Oral Vaccines, by Type USD Million (2023-2028)
  • Table 161. South Korea Oral Vaccines, by Application USD Million (2023-2028)
  • Table 162. South Korea Oral Vaccines, by End Users USD Million (2023-2028)
  • Table 163. Taiwan Oral Vaccines, by Type USD Million (2023-2028)
  • Table 164. Taiwan Oral Vaccines, by Application USD Million (2023-2028)
  • Table 165. Taiwan Oral Vaccines, by End Users USD Million (2023-2028)
  • Table 166. Australia Oral Vaccines, by Type USD Million (2023-2028)
  • Table 167. Australia Oral Vaccines, by Application USD Million (2023-2028)
  • Table 168. Australia Oral Vaccines, by End Users USD Million (2023-2028)
  • Table 169. Rest of Asia-Pacific Oral Vaccines, by Type USD Million (2023-2028)
  • Table 170. Rest of Asia-Pacific Oral Vaccines, by Application USD Million (2023-2028)
  • Table 171. Rest of Asia-Pacific Oral Vaccines, by End Users USD Million (2023-2028)
  • Table 172. Europe Oral Vaccines, by Country USD Million (2023-2028)
  • Table 173. Europe Oral Vaccines, by Type USD Million (2023-2028)
  • Table 174. Europe Oral Vaccines, by Application USD Million (2023-2028)
  • Table 175. Europe Oral Vaccines, by End Users USD Million (2023-2028)
  • Table 176. Germany Oral Vaccines, by Type USD Million (2023-2028)
  • Table 177. Germany Oral Vaccines, by Application USD Million (2023-2028)
  • Table 178. Germany Oral Vaccines, by End Users USD Million (2023-2028)
  • Table 179. France Oral Vaccines, by Type USD Million (2023-2028)
  • Table 180. France Oral Vaccines, by Application USD Million (2023-2028)
  • Table 181. France Oral Vaccines, by End Users USD Million (2023-2028)
  • Table 182. Italy Oral Vaccines, by Type USD Million (2023-2028)
  • Table 183. Italy Oral Vaccines, by Application USD Million (2023-2028)
  • Table 184. Italy Oral Vaccines, by End Users USD Million (2023-2028)
  • Table 185. United Kingdom Oral Vaccines, by Type USD Million (2023-2028)
  • Table 186. United Kingdom Oral Vaccines, by Application USD Million (2023-2028)
  • Table 187. United Kingdom Oral Vaccines, by End Users USD Million (2023-2028)
  • Table 188. Netherlands Oral Vaccines, by Type USD Million (2023-2028)
  • Table 189. Netherlands Oral Vaccines, by Application USD Million (2023-2028)
  • Table 190. Netherlands Oral Vaccines, by End Users USD Million (2023-2028)
  • Table 191. Rest of Europe Oral Vaccines, by Type USD Million (2023-2028)
  • Table 192. Rest of Europe Oral Vaccines, by Application USD Million (2023-2028)
  • Table 193. Rest of Europe Oral Vaccines, by End Users USD Million (2023-2028)
  • Table 194. MEA Oral Vaccines, by Country USD Million (2023-2028)
  • Table 195. MEA Oral Vaccines, by Type USD Million (2023-2028)
  • Table 196. MEA Oral Vaccines, by Application USD Million (2023-2028)
  • Table 197. MEA Oral Vaccines, by End Users USD Million (2023-2028)
  • Table 198. Middle East Oral Vaccines, by Type USD Million (2023-2028)
  • Table 199. Middle East Oral Vaccines, by Application USD Million (2023-2028)
  • Table 200. Middle East Oral Vaccines, by End Users USD Million (2023-2028)
  • Table 201. Africa Oral Vaccines, by Type USD Million (2023-2028)
  • Table 202. Africa Oral Vaccines, by Application USD Million (2023-2028)
  • Table 203. Africa Oral Vaccines, by End Users USD Million (2023-2028)
  • Table 204. North America Oral Vaccines, by Country USD Million (2023-2028)
  • Table 205. North America Oral Vaccines, by Type USD Million (2023-2028)
  • Table 206. North America Oral Vaccines, by Application USD Million (2023-2028)
  • Table 207. North America Oral Vaccines, by End Users USD Million (2023-2028)
  • Table 208. United States Oral Vaccines, by Type USD Million (2023-2028)
  • Table 209. United States Oral Vaccines, by Application USD Million (2023-2028)
  • Table 210. United States Oral Vaccines, by End Users USD Million (2023-2028)
  • Table 211. Canada Oral Vaccines, by Type USD Million (2023-2028)
  • Table 212. Canada Oral Vaccines, by Application USD Million (2023-2028)
  • Table 213. Canada Oral Vaccines, by End Users USD Million (2023-2028)
  • Table 214. Mexico Oral Vaccines, by Type USD Million (2023-2028)
  • Table 215. Mexico Oral Vaccines, by Application USD Million (2023-2028)
  • Table 216. Mexico Oral Vaccines, by End Users USD Million (2023-2028)
  • Table 217. Research Programs/Design for This Report
  • Table 218. Key Data Information from Secondary Sources
  • Table 219. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Oral Vaccines: by Type USD Million (2017-2022)
  • Figure 5. Global Oral Vaccines: by Application USD Million (2017-2022)
  • Figure 6. Global Oral Vaccines: by End Users USD Million (2017-2022)
  • Figure 7. South America Oral Vaccines Share (%), by Country
  • Figure 8. Asia Pacific Oral Vaccines Share (%), by Country
  • Figure 9. Europe Oral Vaccines Share (%), by Country
  • Figure 10. MEA Oral Vaccines Share (%), by Country
  • Figure 11. North America Oral Vaccines Share (%), by Country
  • Figure 12. Global Oral Vaccines share by Players 2022 (%)
  • Figure 13. Global Oral Vaccines share by Players (Top 3) 2022(%)
  • Figure 14. Global Oral Vaccines share by Players (Top 5) 2022(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. GlaxoSmithKline Plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 17. GlaxoSmithKline Plc. (United Kingdom) Revenue: by Geography 2022
  • Figure 18. Merck & Co. Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Merck & Co. Inc. (United States) Revenue: by Geography 2022
  • Figure 20. Aventis (Sanofi S.A.) (France) Revenue, Net Income and Gross profit
  • Figure 21. Aventis (Sanofi S.A.) (France) Revenue: by Geography 2022
  • Figure 22. Swiss Serum and Vaccine Institute Berne (Switzerland) Revenue, Net Income and Gross profit
  • Figure 23. Swiss Serum and Vaccine Institute Berne (Switzerland) Revenue: by Geography 2022
  • Figure 24. QUÍMICA SUIZA S.A. (Peru) Revenue, Net Income and Gross profit
  • Figure 25. QUÍMICA SUIZA S.A. (Peru) Revenue: by Geography 2022
  • Figure 26. PaxVax Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 27. PaxVax Corporation (United States) Revenue: by Geography 2022
  • Figure 28. VALNEVA Canada Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 29. VALNEVA Canada Inc. (Canada) Revenue: by Geography 2022
  • Figure 30. Janssen Pharmaceuticals (Belgium) Revenue, Net Income and Gross profit
  • Figure 31. Janssen Pharmaceuticals (Belgium) Revenue: by Geography 2022
  • Figure 32. Serum Institute of India Pvt. Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 33. Serum Institute of India Pvt. Ltd. (India) Revenue: by Geography 2022
  • Figure 34. Shanghai BravoBio Co., Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 35. Shanghai BravoBio Co., Ltd. (China) Revenue: by Geography 2022
  • Figure 36. Global Oral Vaccines: by Type USD Million (2023-2028)
  • Figure 37. Global Oral Vaccines: by Application USD Million (2023-2028)
  • Figure 38. Global Oral Vaccines: by End Users USD Million (2023-2028)
  • Figure 39. South America Oral Vaccines Share (%), by Country
  • Figure 40. Asia Pacific Oral Vaccines Share (%), by Country
  • Figure 41. Europe Oral Vaccines Share (%), by Country
  • Figure 42. MEA Oral Vaccines Share (%), by Country
  • Figure 43. North America Oral Vaccines Share (%), by Country
List of companies from research coverage that are profiled in the study
  • GlaxoSmithKline Plc. (United Kingdom)
  • Merck & Co. Inc. (United States)
  • Aventis (Sanofi S.A.) (France)
  • Swiss Serum and Vaccine Institute Berne (Switzerland)
  • QUÍMICA SUIZA S.A. (Peru)
  • PaxVax Corporation (United States)
  • VALNEVA Canada Inc. (Canada)
  • Janssen Pharmaceuticals (Belgium)
  • Serum Institute of India Pvt. Ltd. (India)
  • Shanghai BravoBio Co., Ltd. (China)
Additional players considered in the study are as follows:
TD Vaccines A/S (Denmark) , Crucell Vaccines, Inc. (United States) , Sublimity Therapeutics Limited (Ireland) , International Vaccine Institute (South Korea)
Select User Access Type

Key Highlights of Report


Jun 2023 202 Pages 89 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Oral Vaccines research Quantitative research analysis
Global Oral Vaccines research Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"New Developments in Oral Vaccines" is seen as one of major influencing trends for Oral Vaccines Market during projected period 2022-2028.
The Concentration Rate of Global Oral Vaccines market is highlighted using HHI Index.
United States Players will contribute the maximum growth of Global Oral Vaccines market throughout the predicted period.
North America holds highest share for Oral Vaccines Market .

Know More About Global Oral Vaccines research Report?

Have a Query? Click Here

Other Related Reports

Biobanking Comprehensive Study by Type (Equipment, Consumables, Services, Software), Application (Regenerative Medicine, Life Science Research, Clinical Research), Ownership (National/Regional Agenci...
$ 3750
Clinical Microbiology Comprehensive Study by Application (Pharmaceutical, Food Testing, Energy, Chemical and Material Manufacturing, Environment), End Users (Hospital, Diagnolab, Academia), Disease (...
$ 3750
Animal Hormones Comprehensive Study by Application (Growth Promoters, Performance Enhancers, Others), End-Use (Poultry, Porcine, Livestock, Equine, Aquaculture, Other) Players and Region - Global Mar...
$ 3500
Exosomes Comprehensive Study by Application (Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Others), Downstream Analysis (Cell Surface Marker Analysis using Flow Cy...
$ 3750
Cell Banking Outsourcing Comprehensive Study by Type (Master Cell Banking, Working Cell Banking, Viral Cell Banking), Phase (Preparation, Testing, Characterization), Bank Storage (Master Cell Bank St...
$ 3800
Monoclonal Antibodies Comprehensive Study by Application (Cancer, Rheumatoid arthritis, Multiple sclerosis, Cardiovascular disease, Systemic lupus erythematosus, Crohn's disease, Other), Drug Type (A...
$ 3800